Literature DB >> 2102029

[Effectiveness and tolerance of long-term uricosuric treatment].

H Berg.   

Abstract

In an open-controlled, randomized trial over 24 weeks, the serum uric acid lowering effect of a daily dose of 100 mg allopurinol in combination with 20 mg benzbromarone compared to 300 mg allopurinol only was investigated on a total of 60 patients suffering from hyperuricemia. Both preparations led to a decrease of the serum uric acid value to normal. In those patients however, who had received the combination the reduction of the serum uric acid level was more pronounced. Tolerance was generally good. Side-effects were not reported.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2102029

Source DB:  PubMed          Journal:  Z Gesamte Inn Med        ISSN: 0044-2542


  3 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Allopurinol for chronic gout.

Authors:  Rakhi Seth; Alison S R Kydd; Rachelle Buchbinder; Claire Bombardier; Christopher J Edwards
Journal:  Cochrane Database Syst Rev       Date:  2014-10-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.